Metoprolol-Egis

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Metoprolol-Egis

Property Description
Active ingredient Metoprolol
Form Tablet (Oral), Solution (IV)
Pharmacological class Beta-Blocker (eta1 selective)
General purpose Cardiovascular support
Origin Synthetic

What Type of Medicine is Metoprolol-Egis?

Metoprolol-Egis is a pharmaceutical product containing the active substance metoprolol, which belongs to the class of drugs known as beta-blockers (eta-adrenergic antagonists). This medication is classified as a cardioselective eta1 receptor blocker because it primarily affects the receptors located in the heart muscle. Metoprolol is utilized as a medication for managing essential cardiovascular functions. Developed through chemical synthesis, metoprolol is a synthetic, single-ingredient compound, and it is consistently regulated as a prescription-only medication.


Composition and Available Formulations

The core component providing the therapeutic effect is the active ingredient metoprolol, typically present as either the tartrate or succinate salt, formulated with inert pharmaceutical excipients. The medication is primarily administered via the oral administration route, most frequently available as a tablet; specific forms include both immediate-release and extended-release types, the latter being designed for prolonged absorption. The drug is used to modulate heart activity across its different pharmaceutical forms.


How Does Metoprolol Generally Help the Body?

The general purpose of metoprolol is to exert a therapeutic influence on the cardiovascular system by managing the heart's activity. The drug achieves this by consistently inhibiting the action of natural stress hormones on the eta1 receptors. This physiological action causes a distinct reduction in the heart's workload by both slowing the heart rate and decreasing the force of its contractions. This mechanism is intended to provide stability during periods where the heart is working too hard. Ultimately, the use of this cardioselective beta-blocker supports the efficient, sustained function of the heart by contributing to the lowering of blood pressure and easing mechanical stress.

Regulatory References

  1. WHO Essential Medicines List for Metoprolol
  2. NIH MedlinePlus Drug Information
Advertisements

What side effects are possible with Metoprolol-Egis?

Possible Side Effects and Safety Information

The safety profile for Metoprolol-Egis is based on official government regulatory documentation, which categorizes adverse reactions by frequency and affected body system (System-Organ Class or SOC).

Adverse Reactions by Frequency

The following are some of the documented side effects. Not all possible side effects are listed.

Frequency Category Examples of Adverse Reactions (SOC)
Common (ge 1/100 to <1/10) Fatigue, dizziness, headache, bradycardia (slow heart rate), cold extremities, nausea, vomiting, diarrhea.
Uncommon (ge 1/1,000 to <1/100) Worsening of heart failure symptoms, depression, nightmares, shortness of breath, skin rash.
Rare (ge 1/10,000 to <1/1,000) Impaired cardiac conduction, hair loss (alopecia), dry eyes.

Serious Adverse Reactions

Regulatory sources document that Metoprolol-Egis may cause serious, though rare, adverse reactions, including the aggravation of pre-existing heart failure and severe cardiac conduction abnormalities (e.g., heart block). Immediate medical evaluation is required if signs of severe cardiac events occur.

Population-Specific Safety Statements

  • Hepatic Impairment: Caution is required in patients with severe liver dysfunction, as the clearance of metoprolol may be reduced, potentially necessitating dose adjustment by a healthcare provider.
  • Pregnancy and Lactation: Use during pregnancy requires strict medical monitoring due to the potential risk of fetal bradycardia, hypotension, and hypoglycemia in the neonate. Metoprolol is excreted into breast milk.

Safety-Related Restrictions

Abrupt discontinuation of this medication can be dangerous and may increase the risk of angina exacerbation or myocardial infarction (heart attack). The dosage must be gradually reduced over a period of 1 to 2 weeks under medical guidance. Metoprolol may also mask symptoms of hypoglycemia in diabetic patients and tachycardia associated with hyperthyroidism.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on the officially documented overdose profile of metoprolol as defined by government regulatory authorities.

Overdose Scope

Element Regulatory Statement
Documented Overdose Manifestations Profound bradycardia (excessively slow heart rate), severe hypotension (extremely low blood pressure), and the onset of acute cardiac failure are the primary clinical signs. Other documented presentations include bronchospasm and vomiting.
Physiological Systems Affected The cardiovascular system is critically affected, potentially leading to cardiogenic shock and asystole. Central Nervous System involvement, including coma and respiratory depression, is also documented.
Population-Specific Overdose Notes Pediatric patients are noted in official documents to have increased susceptibility to severe effects, including the risk of profound hypoglycemia and central nervous system compromise.
When Immediate Medical Help is Required Seek immediate medical attention or call emergency services for any suspected overdose. This action is explicitly required when severe or life-threatening symptoms manifest.

Overdose Management (Official Statements)

The regulatory labeling describes the management of overdose as symptomatic and supportive. Specific procedural measures include gastric decontamination (e.g., activated charcoal) and the use of pharmacological agents such as intravenous Glucagon to address severe cardiovascular symptoms. Continuous cardiac monitoring and respiratory support are required components of hospital observation.

Advertisements

Therapeutic Uses of Metoprolol-Egis

What Metoprolol-Egis Treats: Main Uses and Benefits

Metoprolol is commonly used to provide consistent, foundational support for the long-term management of essential hypertension, addressing symptoms that create noticeable physiological strain. The objective of lowering blood pressure is relevant for easing the overall symptom burden. This supportive therapy may assist with reducing the risk of cardiovascular events, addressing symptoms related to systemic imbalance.

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as angina pectoris, stable symptomatic chronic heart failure, and certain rapid heart rhythms. It is also applied in clinical settings that involve recovery from a major cardiac event. The therapy is commonly used to help with managing symptom intensity and may assist with reducing the frequency of episodic manifestations of chest discomfort.

“This supportive benefit helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability during periods of heightened symptoms.”

The therapy is used to help with the overall symptom load associated with chronic conditions and is applied when supportive symptom management is appropriate.

Quick Fact: Relief for Cardiac Strain Metoprolol is relevant for easing symptoms that create noticeable physiological strain, primarily by assisting with maintaining functional stability in conditions characterized by periods of heightened symptoms, such as effort-related chest discomfort and rapid heart rhythms.

Regulatory References

  1. NIH DailyMed Prescribing Information
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Metoprolol-Egis?

Eligibility for metoprolol is governed by a patient’s cardiac status, age, and existing comorbidities, as defined by official regulatory documents.

Population Eligibility
Use Is Established: Adults are eligible for all labeled indications. Pediatric use is established for treating hypertension in children ge 6 years.
Use Not Established: Safety and effectiveness have not been established in children less than 6 years of age.
Conditional Use: Use requires caution in older adults, individuals with diabetes (due to the risk of masking hypoglycemia), bronchospastic disease, and Peripheral Vascular Disease. Dosage adjustments should be considered for severe hepatic impairment, though none is usually needed for chronic renal failure.

Formal Contraindications (Do Not Use)
The medicine is contraindicated (must not be used) in patients with known hypersensitivity, severe bradycardia, cardiogenic shock, decompensated heart failure, or specific severe cardiac conduction disorders (e.g., Second- or Third-Degree Heart Block, or Sick Sinus Syndrome without a pacemaker) [(FDA Prescribing Information)].

Pregnancy and Lactation Status

Metoprolol is not recommended for use during pregnancy unless the potential clinical benefit clearly outweighs the potential risk. However, it is generally considered to pose minimal risk to the infant when used during breastfeeding at therapeutic doses.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Concomitant use of Metoprolol-Egis with certain medicinal products requires caution or is not recommended due to specific regulatory constraints and documented interaction risks.

Interacting Product Category Interaction Implication Constraint/Requirement (as per label)
Calcium Channel Blockers (Verapamil, Diltiazem) Potentiated depressant effects on heart rate and conduction. Intravenous Verapamil is generally contraindicated; the combination requires close monitoring.
CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Propafenone) Significant increase in metoprolol plasma concentration. Monitor closely; dose adjustment may be necessary, particularly in poor metabolizers.
Clonidine Risk of exacerbated rebound hypertension upon withdrawal. Metoprolol must be withdrawn several days before the gradual withdrawal of clonidine.
Cardiac Glycosides (e.g., Digoxin) and other drugs that decrease heart rate Additive effects on slowing the heart rate and AV conduction. Close monitoring of heart rate and rhythm is required.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Indomethacin) Possible reduction in the antihypertensive effects of Metoprolol-Egis. The potential for reduced blood pressure control should be noted.

Metoprolol is primarily metabolized by the CYP2D6 enzyme. Medicines that strongly inhibit this enzyme, such as certain anti-arrhythmics and antidepressants, can lead to elevated metoprolol exposure. Conversely, strong enzyme inducers like Rifampicin may decrease metoprolol plasma levels. Patients with diabetes should be aware that Metoprolol-Egis may mask warning signs of hypoglycemia, such as tachycardia, when taken with Insulin or Oral Hypoglycaemic Drugs. If Metoprolol-Egis is used in patients with pheochromocytoma, it must be started only after an alpha-blocker has been initiated.

Advertisements

Mechanism of Action

Molecular Blockade of Cardiac Stress Signals

Metoprolol's mechanism begins as a competitive antagonist primarily targeting the beta1-adrenergic receptors found in the heart. By blocking these key docking points, the drug prevents the binding of natural stress hormones, Norepinephrine and Epinephrine, reducing the sympathetic influence on the heart by occupying the beta1-adrenergic receptors. This interruption of the signal cascade immediately reduces the rate of electrical impulse generation and the force of contraction.

Modulation of Core Cardiovascular Pathways

The molecular blockade leads directly to two core physiological changes: a negative chronotropic effect (slowing the heart rate) and a negative inotropic effect (reducing contractile force). Additionally, metoprolol inhibits the beta1-receptors on specialized kidney cells, suppressing the release of renin and modulating the Renin-Angiotensin-Aldosterone System (RAAS). These combined actions lead to a decrease in the heart's oxygen demand and energy consumption, while simultaneously contributing to the modulation of systemic vascular pressure.

Advertisements

Dosage and Administration Information

Administration Routes and Formulations

Metoprolol-Egis is administered primarily via the oral route using either immediate-release (metoprolol tartrate) or extended-release (metoprolol succinate) tablets. The tablets are available in a range of strengths from 12.5 mg to 200 mg in the extended-release form. An intravenous (IV) solution is available for controlled use in acute, monitored settings.


Official Dosing and Titration Schedules

Standard therapeutic regimens typically begin with a low initial dose, ranging from 25 mg to 100 mg daily. For certain chronic conditions, such as heart failure, the initial dose is lower (e.g., 12.5 mg or 25 mg extended-release) and is gradually increased (titrated). Dosage adjustments are made over defined intervals, typically one week or longer, until the maintenance range is reached, which may be up to 400 mg daily.


Timing, Frequency, and Handling

Administration frequency is usually once daily for the extended-release formulation and may be in divided doses for the immediate-release form. Standard administration guidelines specify that immediate-release tablets should be taken with or immediately following a meal to optimize use. Extended-release tablets can be taken with or without food but must be swallowed whole and must not be crushed or chewed.


Population-Specific and Procedural Rules

Therapy is typically initiated at low doses and titrated cautiously for patients with hepatic impairment. Clinical guidelines generally indicate that dose adjustment is not required for patients with renal impairment. If treatment is to be discontinued, the dosage is gradually reduced over a period of one to two weeks, following a defined tapering schedule.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Clinical evidence on metoprolol, the active ingredient in Metoprolol-Egis, primarily focuses on its established use as a beta-blocker in managing cardiovascular conditions. Research continues to investigate its profile in specific patient populations and long-term treatment scenarios.


Use in Heart Failure

Large-scale clinical trials have investigated the role of metoprolol succinate, the extended-release form, in patients with chronic heart failure (CHF). Studies demonstrated that the initiation of therapy, following a gradual titration period, was associated with improvements in clinical status and reductions in combined endpoints such as all-cause mortality and heart failure hospitalization in patients with stable, mild to severe CHF. These findings established metoprolol as a cornerstone treatment for certain types of heart failure.


Post-Myocardial Infarction Management

Decades of research have shown that metoprolol is associated with improved long-term outcomes following an acute myocardial infarction (heart attack). Studies generally show that administering metoprolol to clinically stable patients can contribute to stabilizing heart rhythm and reducing the risk of subsequent cardiac events. The decision to initiate and maintain treatment is highly dependent on the patient’s overall clinical profile and risk assessment.


Blood Pressure and Angina Control

Metoprolol is widely studied for its effectiveness in reducing blood pressure (hypertension) and decreasing the frequency and severity of angina pectoris (chest pain). Clinical data confirm its capacity to reduce heart rate and contractility, thereby lowering oxygen demand on the heart and helping manage symptoms related to coronary artery disease.

Key Studies & References

  1. Randomized Evaluation of Decreased Usage of Beta-Blockers After Acute Myocardial Infarction (REDUCE-AMI)
  2. Metoprolol: MedlinePlus Drug Information
  3. Metoprolol - StatPearls (General Clinical Overview and Indications)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Metoprolol-Egis (FAQ)


Q: Can alcohol be consumed while a person is using Metoprolol-Egis?

A: Official information indicates that consuming alcohol while using Metoprolol-Egis may increase certain side effects, such as dizziness, light-headedness, or feeling tired. This happens because alcohol can have additive effects with the medication. Regulatory documents typically state that alcohol may increase side effects, and patients should be aware of this potential interaction.


Q: Does using Metoprolol-Egis affect a person's ability to drive or operate machinery?

A: Regulatory documents state that Metoprolol-Egis can cause side effects like dizziness, tiredness, or light-headedness, particularly when first starting the medicine or after a dose change. Due to the potential for these effects, patients are advised in the product label to use caution regarding activities such as driving until the drug's effect is known.


Q: Can Metoprolol-Egis be crushed or split?

A: The required handling of Metoprolol-Egis depends on the formulation used. Official product information for extended-release tablets often states they may be divided if they are scored, but the halves must not be crushed or chewed to preserve the controlled release mechanism. The specific instruction is often best clarified with a healthcare provider regarding the exact product.


Q: Is it described as safe to take Metoprolol-Egis with antacids?

A: Some antacids, particularly those containing ingredients like calcium carbonate, may decrease the absorption of metoprolol in the body. This could potentially reduce the medicine's effectiveness. Official guidance sometimes notes that separating the administration times by at least two hours may be considered to help maintain metoprolol absorption.


Q: Is Metoprolol-Egis a controlled substance?

A: Metoprolol is consistently regulated as a prescription-only medication in most countries. According to standard regulatory classifications, the active ingredient metoprolol is not typically defined as a federally controlled substance in the US.


Q: Do the side effects of Metoprolol-Egis usually go away after a while?

A: Patient information leaflets often note that common side effects, such as headaches and dizziness, are generally mild and may improve or go away after the first few weeks of consistent use. Any persistent or severe side effects are typically addressed in consultation with a healthcare professional.


Q: What kind of foods or drinks should people be cautious about while using Metoprolol-Egis?

A: The immediate-release tablets are officially advised to be taken with or immediately following a meal because food can increase the medicine's absorption. Regulatory information also notes the potential for increased side effects if alcohol is consumed.


Q: What should be done if a person forgets to take a dose?

A: General regulatory information describes specific steps for a missed dose, often stating it can be taken as soon as a person remembers. However, if it is nearly time for the next scheduled dose, the missed dose is usually skipped entirely. The instructions vary based on the specific formulation, and patients should refer to their product’s leaflet.


Q: Does Metoprolol-Egis affect cholesterol levels?

A: Official adverse reaction documents list potential changes in the levels of blood lipids (fats) as documented findings from investigations. Specifically, this may include both increased blood triglycerides and a decrease in HDL cholesterol (often referred to as 'good' cholesterol).


Q: Is Metoprolol-Egis known to cause weight gain?

A: Official product labeling lists unusual weight gain or loss as a reported adverse reaction in some patient information. The frequency of this occurrence is often listed as incidence not known or rare.


Q: Is there a generic version available for Metoprolol-Egis?

A: The active ingredient in Metoprolol-Egis, metoprolol, is widely recognized and available in many countries in generic formulations. These generics are available as both metoprolol tartrate (immediate-release) and metoprolol succinate (extended-release) salts.


Q: Is Metoprolol-Egis known to affect sexual function?

A: Regulatory adverse reaction tables include potential effects on sexual function. These documented side effects may include decreased libido (a reduced interest in sexual activity) and, in some cases, impotence (difficulty achieving or maintaining an erection).


Q: Does Metoprolol-Egis interact with St. John's Wort?

A: Regulatory drug interaction information notes that Metoprolol is metabolized by the CYP2D6 enzyme. St. John's Wort is known to be a strong CYP2D6 enzyme inducer, which may cause the body to break down the metoprolol faster. This effect may result in decreased metoprolol levels and potentially reduced effectiveness.

Advertisements

How should Metoprolol-Egis be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory agencies define strict conditions to maintain the stability and safety of Metoprolol-Egis tablets. The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from excess heat and moisture. It is required to keep the medication in the original container and ensure the cap is tightly closed; storage in high-humidity areas like the bathroom is advised against.

A mandatory storage rule requires keeping the container out of the sight and reach of children and pets, utilizing safety caps. For disposal, official protocols recommend utilizing a local drug take-back program. It is strictly prohibited to flush the unused medication down the toilet or dispose of it in household wastewater, as these measures help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metoprolol-Egis found in:

A-Z Index: